GC Biopharma Corp. (KRX:006280)

GC Biopharma Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 7, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	1,627,512	1,814,695	2,048,665	1,432,354	1,478,007	2,488,073
Market Cap Growth	12.99%	-11.42%	43.03%	-3.09%	-40.60%	-46.30%
Enterprise Value	2,735,647	2,959,257	3,129,049	2,368,951	2,204,898	3,075,936
Last Close Price	142600.00	157420.53	177716.89	123165.91	125551.64	208663.39
PE Ratio	-	-	-	-	22.58	20.19
Forward PE	36.58	28.99	87.99	47.35	21.09	25.00
PS Ratio	0.82	0.91	1.22	0.88	0.86	1.62
PB Ratio	1.17	1.30	1.38	0.93	0.94	1.66
P/TBV Ratio	1.67	1.86	1.94	1.34	1.33	2.31
P/FCF Ratio	60.05	66.96	-	-	24.17	105.17
P/OCF Ratio	16.36	18.25	-	-	12.40	19.75
PEG Ratio	-	1.35	1.35	1.35	1.35	1.20
EV/Sales Ratio	1.37	1.49	1.86	1.46	1.29	2.00
EV/EBITDA Ratio	13.85	19.04	27.67	21.57	15.12	23.73
EV/EBIT Ratio	24.91	43.64	97.66	69.86	27.32	41.72
EV/FCF Ratio	100.94	109.20	-	-	36.05	130.02
Debt / Equity Ratio	0.70	0.70	0.56	0.47	0.37	0.40
Debt / EBITDA Ratio	6.32	6.32	7.32	6.59	3.95	4.68
Debt / FCF Ratio	36.24	36.24	-	-	9.41	25.64
Net Debt / Equity Ratio	0.67	0.67	0.54	0.43	0.30	0.27
Net Debt / EBITDA Ratio	5.99	5.99	7.11	6.09	3.18	3.11
Net Debt / FCF Ratio	34.37	34.37	-9.41	-7.91	7.57	17.06
Asset Turnover	0.70	0.70	0.62	0.63	0.69	0.67
Inventory Turnover	1.76	1.76	1.90	2.38	2.52	2.28
Quick Ratio	0.40	0.40	0.55	0.58	0.96	1.13
Current Ratio	1.20	1.20	1.56	1.20	1.81	1.97
Return on Equity (ROE)	-2.07%	-2.07%	-2.82%	-1.27%	4.53%	9.89%
Return on Assets (ROA)	1.48%	1.48%	0.74%	0.82%	2.02%	2.00%
Return on Invested Capital (ROIC)	2.84%	2.94%	1.43%	1.60%	3.32%	3.36%
Return on Capital Employed (ROCE)	3.70%	3.70%	1.60%	1.90%	4.10%	3.90%
Earnings Yield	-0.29%	-0.26%	-1.28%	-1.86%	4.43%	4.95%
FCF Yield	1.67%	1.49%	-4.17%	-5.90%	4.14%	0.95%
Payout Ratio	-	-	-	-	36.65%	15.02%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.